Pioglitazone Is Associated with Excess Risk for Bladder Cancer

Summary and Comment |
June 21, 2012

Pioglitazone Is Associated with Excess Risk for Bladder Cancer

  1. Paul S. Mueller, MD, MPH, FACP

Using pioglitazone for >2 years or exceeding a cumulative dose of 28,000 mg imparted the highest risk.

  1. Paul S. Mueller, MD, MPH, FACP

In 2011, the FDA issued a safety warning for the antidiabetic drug pioglitazone (Actos). The warning states that use for longer than 1 year might be associated with excess risk for bladder cancer, based on data from a French study and an interim analysis of a manufacturer-sponsored, U.S. observational study. U.K. investigators now report on a case-control study in which they evaluated the same outcome.

Researchers identified 116,000 patients (mean age, 64) with type 2 diabetes who were new users of oral antidiabetic drugs. After a mean follow-up of 4.6 years, 470 patients had received diagnoses of bladder cancer (89 cases per 100,000 person-years). Each patient with bladder cancer was matched with as many as 20 controls. Ever use of pioglitazone was associated with 83% higher risk for bladder cancer — a significant increase — compared with never users. The bladder cancer rate increased significantly with duration of pioglitazone use, with the highest rates in patients who were exposed for >2 years, and in patients whose cumulative dose exceeded 28,000 mg. Notably, no excess risk for bladder cancer was observed for patients who received rosiglitazone (Avandia).

Comment

In this study, pioglitazone use was associated with excess risk for bladder cancer in patients with type 2 diabetes. Because these findings reinforce the FDA warning, clinicians and patients should weigh carefully the benefits and risks of using this drug.

Citation(s):

Your Comment

(will not be published)

Filtered HTML

  • Allowed HTML tags: <a> <em> <strong> <cite> <blockquote> <code> <ul> <ol> <li> <dl> <dt> <dd>
  • Web page addresses and e-mail addresses turn into links automatically.
  • Lines and paragraphs break automatically.

Plain text

  • No HTML tags allowed.
  • Web page addresses and e-mail addresses turn into links automatically.
  • Lines and paragraphs break automatically.
Do you have any conflict of interest to disclose?
CAPTCHA
This question is for testing whether you are a human visitor and to prevent automated spam submissions.

Vertical Tabs

* Required

Reader comments are intended to encourage lively discussion of clinical topics with your peers in the medical community. We ask that you keep your remarks to a reasonable length, and we reserve the right to withhold publication of remarks that do not meet this standard.

PRIVACY: We will not use your email address, submitted for a comment, for any other purpose nor sell, rent, or share your e-mail address with any third parties. Please see our Privacy Policy.